{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T08:43:19Z","timestamp":1784191399979,"version":"3.55.0"},"reference-count":31,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2018,2,2]],"date-time":"2018-02-02T00:00:00Z","timestamp":1517529600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004324","name":"Astellas Pharma US","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004324","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Mycoses"],"published-print":{"date-parts":[[2018,5]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>Neutropenia is linked to the development of invasive candidiasis\/candidaemia, for which micafungin has demonstrated efficacy, but evidence in patients with neutropenia is limited. The aim of this study was to evaluate the efficacy of micafungin for the treatment of invasive candidiasis\/candidaemia in patients with neutropenia (&lt;500\u00a0neutrophils\/\u03bcL) and without neutropenia. This pooled, <jats:italic>post hoc<\/jats:italic> analysis of 2 Phase 3 trials compared micafungin 100\u00a0mg\/d (adults) and 2\u00a0mg\/kg\/d (paediatrics) with L\u2010AmB 3\u00a0mg\/kg\/d (<jats:styled-content style=\"fixed-case\">NCT<\/jats:styled-content>00106288) and micafungin 100\u00a0mg\/d and 150\u00a0mg\/d with caspofungin 70\u00a0mg\/d followed by 50\u00a0mg\/d (adults) (<jats:styled-content style=\"fixed-case\">NCT<\/jats:styled-content>00105144); treatment duration 2\u20104\u00a0weeks (\u22648\u00a0weeks for chronic disseminated candidiasis). Effects of neutropenia duration and <jats:italic>Candida<\/jats:italic> spp. on efficacy outcomes (treatment success, clinical and mycological response) were examined. Of 685 patients, 77 had neutropenia. The most common infection in patients with\/without neutropenia was due to <jats:italic>C.\u00a0tropicalis<\/jats:italic> (31\/77) and <jats:italic>C.\u00a0albicans<\/jats:italic> (295\/608) respectively. Overall success was numerically lower in patients with vs without neutropenia (63.6% vs 72.9%). Clinical and mycological response was similar between groups. Neutropenia duration or <jats:italic>Candida<\/jats:italic> spp. did not impact micafungin's overall success rate. This analysis supports evidence that micafungin is effective against invasive candidiasis\/candidaemia in patients with neutropenia, irrespective of neutropenia duration or <jats:italic>Candida<\/jats:italic> spp., although overall success may be lower than in patients without neutropenia.<\/jats:p>","DOI":"10.1111\/myc.12748","type":"journal-article","created":{"date-parts":[[2018,1,24]],"date-time":"2018-01-24T16:32:45Z","timestamp":1516811565000},"page":"331-336","source":"Crossref","is-referenced-by-count":12,"title":["Efficacy of micafungin for the treatment of invasive candidiasis and candidaemia in patients with neutropenia"],"prefix":"10.1111","volume":"61","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0774-1058","authenticated-orcid":false,"given":"Pranatharthi","family":"Chandrasekar","sequence":"first","affiliation":[{"name":"Division of Infectious Diseases Department of Internal Medicine Wayne State University, Karmanos Cancer Center  Detroit MI USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhawna","family":"Sirohi","sequence":"additional","affiliation":[{"name":"Barts Health NHS Trust  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nita L.","family":"Seibel","sequence":"additional","affiliation":[{"name":"Cancer Therapy Evaluation Program National Cancer Institute  Bethesda MD USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jack W.","family":"Hsu","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology Department of Medicine University of Florida  Gainesville FL USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nkechi","family":"Azie","sequence":"additional","affiliation":[{"name":"Astellas Pharma Global Development, Inc.  Northbrook IL USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunzhang","family":"Wu","sequence":"additional","affiliation":[{"name":"Astellas Pharma Global Development, Inc.  Northbrook IL USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Ruhnke","sequence":"additional","affiliation":[{"name":"Charit\u00e9 University Medicine Humboldt University  Berlin Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2018,2,2]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2012.06.012"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/civ293"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1086\/599039"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2334-6-50"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/myc.12013"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1086\/320757"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/1469-0691.12312"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2013.1.423"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cis021"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2014.05.015"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1086\/514731"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0959-8049(99)00052-0"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2012.745073"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.21615"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1439-0507.2011.02045.x"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa066906"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/civ933"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/1469-0691.12041"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200868150-00010"},{"key":"e_1_2_8_21_1","unstructured":"European Medicines Agency.Assessment report for mycamine.2008;http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Public_assessment_report\/human\/000734\/WC500031079.pdf. Accessed 5 May 2017."},{"key":"e_1_2_8_22_1","unstructured":"Astellas Pharma US Inc.Mycamine label.2013;http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2011\/021506s011s012lbl.pdf. Accessed 5 May 2017."},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)60605-9"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1086\/520980"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1097\/INF.0b013e31817275e6"},{"key":"e_1_2_8_26_1","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1155\/2014\/983724","article-title":"Micafungin compared with caspofungin for the treatment of febrile episodes in neutropenic patients with hematological malignancies: a retrospective study","volume":"25","author":"Shalhoub S","year":"2014","journal-title":"Can J Infect Dis Med Microbiol"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkx116"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9343(98)00030-8"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10096-009-0843-0"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1023\/A:1008308923252"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.1086\/646024"},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhin.2005.02.009"}],"container-title":["Mycoses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fmyc.12748","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/myc.12748","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,18]],"date-time":"2023-09-18T11:31:43Z","timestamp":1695036703000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/myc.12748"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2,2]]},"references-count":31,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018,5]]}},"alternative-id":["10.1111\/myc.12748"],"URL":"https:\/\/doi.org\/10.1111\/myc.12748","archive":["Portico"],"relation":{},"ISSN":["0933-7407","1439-0507"],"issn-type":[{"value":"0933-7407","type":"print"},{"value":"1439-0507","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,2,2]]}}}